Schroder Investment Management Group Buys 438,887 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Schroder Investment Management Group raised its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 523.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 522,657 shares of the biotechnology company's stock after purchasing an additional 438,887 shares during the period. Schroder Investment Management Group owned about 0.25% of BioCryst Pharmaceuticals worth $3,936,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. increased its position in BioCryst Pharmaceuticals by 7.8% in the fourth quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company's stock worth $164,616,000 after buying an additional 1,583,826 shares during the period. Geode Capital Management LLC increased its holdings in shares of BioCryst Pharmaceuticals by 2.7% during the third quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company's stock valued at $36,776,000 after purchasing an additional 127,708 shares during the period. Two Sigma Advisers LP increased its holdings in shares of BioCryst Pharmaceuticals by 13.6% during the third quarter. Two Sigma Advisers LP now owns 2,181,012 shares of the biotechnology company's stock valued at $16,576,000 after purchasing an additional 261,500 shares during the period. FMR LLC increased its holdings in shares of BioCryst Pharmaceuticals by 2.4% during the third quarter. FMR LLC now owns 1,988,389 shares of the biotechnology company's stock valued at $15,112,000 after purchasing an additional 46,110 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its holdings in BioCryst Pharmaceuticals by 4.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,979,992 shares of the biotechnology company's stock worth $14,890,000 after acquiring an additional 91,998 shares during the period. 85.88% of the stock is owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Stock Performance

Shares of BioCryst Pharmaceuticals stock traded down $0.50 during trading on Thursday, hitting $6.27. 541,577 shares of the stock traded hands, compared to its average volume of 2,792,572. The stock has a market cap of $1.31 billion, a P/E ratio of -10.28 and a beta of 1.75. BioCryst Pharmaceuticals, Inc. has a twelve month low of $4.03 and a twelve month high of $9.50. The company has a fifty day moving average price of $8.01 and a two-hundred day moving average price of $7.76.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.06). The company had revenue of $131.50 million during the quarter, compared to analyst estimates of $126.64 million. During the same quarter last year, the firm earned $0.28 earnings per share. The business's quarterly revenue was up 40.8% compared to the same quarter last year. On average, equities research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on BCRX shares. Wedbush began coverage on BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They set an "outperform" rating and a $15.00 target price on the stock. Royal Bank of Canada restated an "outperform" rating and set a $11.00 price objective (up from $10.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. Evercore ISI raised their price objective on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an "outperform" rating in a research report on Monday, January 13th. HC Wainwright restated a "buy" rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. Finally, Needham & Company LLC restated a "buy" rating and set a $15.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Thursday. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat, BioCryst Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $15.57.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.